ANERIA
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

ANERIA Trademark

Serial Number: 88837767

ANERIA is a trademark filed by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED on March 17, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (253 trademarks)

CLONSHAUGH BUSINESS & TECHNOLOGY PARK
COOLOCK, DUBLIN 17 , IE

Entity Type: 77

Trademark Details

Filing Date

March 17, 2020

Registration Date

Not Registered

Published for Opposition

July 7, 2020

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Apr 4, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 4, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 10, 2021 EXRA
SOU EXTENSION 2 GRANTED
Aug 6, 2021 EX2G
SOU EXTENSION 2 FILED
Aug 6, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 6, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 2, 2021 EXRA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 26, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 26, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 26, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 26, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 26, 2021 COAR
SOU EXTENSION 1 GRANTED
Feb 26, 2021 EX1G
SOU EXTENSION 1 FILED
Feb 26, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 26, 2021 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 25, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 25, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 25, 2021 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 1, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 7, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jul 7, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 17, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 3, 2020 CNSA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 27, 2020 GNRN
NON-FINAL ACTION E-MAILED
May 27, 2020 GNRT
NON-FINAL ACTION WRITTEN
May 27, 2020 CNRT
ASSIGNED TO EXAMINER
May 22, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 21, 2020 NWOS
NEW APPLICATION ENTERED
Mar 20, 2020 NWAP